In univariable analysis, EZH2/BCL2 co-expression was significantly associated with worse EFS in the whole cohort (HR 2.40; p = 0.029) and in the DLBCL-NOS group (HR 2.50; p = 0.043), as well as with worse OS (HR 3.53; p = 0.001) in all patients. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.